25
Participants
Start Date
August 6, 2012
Primary Completion Date
January 31, 2017
Study Completion Date
August 6, 2019
Everolimus
Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital, Athens
Dept of Medical Oncology, 251 General Airforce Hospital, Athens
"2nd Dept of Internal Medicine, General Hospital of Athens Hippokratio", Athens
"2nd Dept of Internal Medicine, Propaedeutic, University Hospital Attikon", Athens
"4th Dept of Internal Medicine, University Hospital Attiko", Athens
3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens
2nd Dept of Medical Oncology, Metropolitan Hospital, Athens
Division of Oncology, Dept of Internal Medicine, University Hospital of Patras, Pátrai
Dept of Medical Oncology, Ioannina University Hospital, Ioannina
Dept of Medical Oncology, Papageorgiou General Hospital, Thessaloniki
Dept of Medical Oncology, Thermi Clinic, Thessaloniki
Dept of Medical Oncology, University Hospital of Heraklion, Heraklion
Collaborators (1)
Novartis
INDUSTRY
Hellenic Cooperative Oncology Group
OTHER